SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-15-016937
Filing Date
2015-01-22
Accepted
2015-01-22 08:51:00
Documents
5
Period of Report
2015-01-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d856103d8k.htm 8-K 18903
2 EXHIBIT 4.5 d856103dex45.htm EX-4.5 71254
3 EXHIBIT 10.45 d856103dex1045.htm EX-10.45 70782
4 EXHIBIT 99.1 d856103dex991.htm EX-99.1 8720
5 GRAPHIC g856103ex99_1logo.jpg GRAPHIC 6622
  Complete submission text file 0001193125-15-016937.txt   180334
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 15540240
SIC: 2834 Pharmaceutical Preparations